#1 Clinical Trials Search in Europe

Study Comparing Custodiol-N and Custodiol for Heart Surgery in Children with Congenital Heart Defects

2 1 1 1

What is this study about?

This clinical trial is focused on studying a condition known as in children. This condition involves structural problems with the heart that are present from birth. The study will compare two different solutions used during heart surgery to protect the heart. These solutions are called and . Custodiol-N is a solution for organ preservation, containing substances like , , and , while Custodiol is a solution for cardioplegia, which includes substances such as , , and . The purpose of the study is to assess the safety of these solutions during surgery.

Participants in the study will undergo heart surgery due to congenital heart malformation. During the surgery, one of the two solutions will be used to protect the heart. The study will monitor the safety of these solutions by observing any adverse events, which are unexpected medical problems, for up to 30 days after the surgery. Additionally, the study will evaluate how well the heart is protected by measuring certain enzymes in the blood, like CK-MB, which can indicate heart muscle damage, until seven days after the surgery.

The study will also gather information on various aspects of the participants’ recovery, such as heart function, hospital stay duration, and any need for additional heart support. This includes monitoring vital signs, blood parameters, and the use of medications like catecholamines and milrinone, which help support heart function. The study aims to provide valuable insights into the effectiveness and safety of these solutions in protecting the heart during surgery for congenital heart malformation in children.

1 enrollment

Eligibility is determined based on age (from birth to less than 18 years) and the need for congenital heart surgery with cardiopulmonary bypass and cardioplegia.

Written informed consent from the patient or their legal guardians is required before joining the study.

2 pre-surgery preparation

The patient is prepared for surgery, which involves the use of cardioplegia solutions: Custodiol-N or Custodiol.

These solutions are administered through infiltration to protect the heart during surgery.

3 surgery

The surgery is performed to correct congenital heart malformations.

During the procedure, the chosen cardioplegia solution is used to protect the heart.

4 post-surgery monitoring

Continuous monitoring for adverse events is conducted for up to 30 days after surgery.

Heart protection is assessed by measuring CK-MB levels, a marker of heart muscle injury, until 7 days after surgery.

5 follow-up assessments

Various assessments are conducted, including hemodynamics, echo, and cardiac injury markers like creatinine kinase and troponin.

The duration of hospital and ICU stay, as well as any readmissions or deaths, are recorded.

Additional evaluations include 12-lead ECG and monitoring for cardiac arrhythmias, including the need for a pacemaker.

Who Can Join the Study?

  • The patient must be from birth to less than 18 years old.
  • The patient must have undergone congenital heart surgery. This is a type of surgery to fix heart problems that are present from birth.
  • The surgery must include cardiopulmonary bypass and cardioplegia. Cardiopulmonary bypass is a technique that temporarily takes over the function of the heart and lungs during surgery. Cardioplegia is a method used to protect the heart during surgery by stopping it from beating.
  • There must be a written informed consent from the patient and/or their legal guardians. This means they must agree to participate in the study after being fully informed about it.
  • The legal guardians must be able to understand the nature and individual consequences of the clinical trial. This means they need to understand what the study involves and how it might affect the patient.

Who Cannot Join the Study?

  • Patients with other serious health conditions that could interfere with the study.
  • Patients who have had a recent surgery or medical procedure that might affect the study results.
  • Patients who are currently participating in another clinical trial.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients with allergies or reactions to any of the study medications or treatments.
  • Patients who are pregnant or breastfeeding.
  • Patients with a history of drug or alcohol abuse.
  • Patients with certain infections that could impact the study.
  • Patients who have received certain medications that could interfere with the study.
  • Patients with a history of certain heart conditions that are not related to the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Deutsches Herzzentrum Muenchen Des Freistaates Bayern Klinik An Der Technischen Universitaet Muenchen Munich Germany
Justus-Liebig-Universitaet Giessen Giessen Germany
Ughudnrxozlhthghdjgnp Mfbitryw Aws Munster Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not yet recruiting
31.03.2025

Trial locations

Investigated drugs:

Custodiol-N is a solution used during heart surgery to protect the heart muscle. It helps to stop the heart safely and preserve its function while the surgery is being performed. This solution is specifically designed to be used in children undergoing surgery for congenital heart defects.

Custodiol is another type of solution used in heart surgery for myocardial protection. Like Custodiol-N, it is used to stop the heart and protect it during surgery. This solution is also used in pediatric patients with congenital heart malformations.

Investigated diseases:

Congenital Heart Malformation in Children – This condition involves structural abnormalities of the heart present at birth. These malformations can affect the heart’s walls, valves, or blood vessels, impacting how blood flows through the heart and to the rest of the body. The progression of the disease varies widely depending on the type and severity of the malformation. Some children may experience symptoms such as difficulty breathing, poor feeding, or delayed growth. In some cases, the condition may remain stable, while in others, it may lead to complications that require medical intervention. Regular monitoring and assessment are often necessary to manage the condition effectively.

Trial ID:
2024-511517-38-00
Protocol code:
CL-N-CP-Paed
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on Allopurinol Sodium for Brain Injury Prevention in Newborns with Critical Congenital Heart Disease Undergoing Heart Surgery

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Theophylline for Improving Exercise Capacity in Adolescents with Univentricular Heart Disease and Fontan Circulation

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway